Celadon’s focus is on developing novel cannabis-based prescription medicines that can be taken through clinical trials. This includes the discovery of novel cannabinoid-derived molecules and new delivery technologies. The programme is led by a highly experienced in-house team of drug development professionals, in combination with leading industry partnerships.
Celadon’s R&D programme is currently focused on three priorities:
Kingdom Therapeutics is an early-stage biopharma focused on securing a fully
licensed cannabinoid-based treatment for Autism Spectrum Disorder (ASD).
Kingdom’s team are leaders in cannabinoids, ASD and inflammation
Autism is a significant opportunity, with an estimated market size of over $5bn by 2027 and limited drug options currently. Kingdom’s research drug, KT-20610, is being developed to treat an estimated patient population of over 500k children in USA alone. The treatment targets the link between gastrointestinal permeability (excessive gut leakiness) and ASD and is backed by compelling pre-clinical data which shows that the lead product can significantly reduce gastrointestinal permeability and improve both behavioural and gastrointestinal function in ASD.
Celadon was an early investor in Kingdom and now has a circa 20% stake in the business. Additionally, Celadon has secured a supply agreement for the natural API that goes into KT-20610. If Kingdom’s treatment is successful, this will create significant demand for Celadon’s API.